Intramyocellular lipids and insulin resistance

Diabetes, Obesity and Metabolism

Volumn 6, Issue 4, 2004, Pages 239-248

  Machann, Jürgen ^a   Häring, Hans ^a   Shick, Fritz ^a   Stumvoll, Michael ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Insulin sensitivity; Magnetic resonance spectroscopy; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; FAT DROPLET; FATTY ACID; INSULIN; LIPID; PIOGLITAZONE; ROSIGLITAZONE;

ADIPOCYTE; AEROBIC CAPACITY; COHORT ANALYSIS; CORRELATION ANALYSIS; CYTOPLASM; DRUG MECHANISM; FITNESS; HEREDITY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC PARAMETERS; MOLECULAR MECHANICS; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; RELIABILITY; REVIEW; SKELETAL MUSCLE;

EID: 3042634520     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1462-8902.2004.00339.x     Document Type: Review

References (74)

1. Denton RM, Randle PJ. Concentrations of glycerides and phospholipids in rat heart and gastrocnemius muscles. Effects of alloxan-diabetes and perfusion. Biochem J 1967; 104: 416-422.
2. Dagenais GR, Tancredi RG, Zierler KL. Free fatty acid oxidation by forearm muscle at rest, and evidence for an intramuscular lipid pool in the human forearm. J Clin Invest 1976; 58: 421-431.
3. Frayn KN, Maycock PF. Skeletal muscle triacylglycerol in the rat: methods for sampling and measurement, and studies of biological variability. J Lipid Res 1980; 21: 139-144.
4. Schick F, Eismann B, Jung WI, Bongers H, Bunse M, Lutz O. Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue. Magn Reson Med 1993; 29: 158-167.
5. Wendling PS, Peters SJ, Heigenhauser GJ, Spriet LL. Variability of triacylglycerol content in human skeletal muscle biopsy samples. J Appl Physiol 1996; 81: 1150-1155.
6. Howald H, Boesch C, Kreis R et al. Content of intramyocellular lipids derived by electron microscopy, biochemical assays, and (1)H-MR spectroscopy. J Appl Physiol 2002; 92: 2264-2272.
7. He J, Watkins S, Kelley DE. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes 2001; 50: 817-823.
8. Standl E, Lotz N, Dexel T, Janka HU, Kolb HJ. Muscle triglycerides in diabetic subjects. Effect of insulin deficiency and exercise. Diabetologia 1980; 18: 463-469.
9. Falholt K, Cutfield R, Alejandro R, Heding L, Mintz D. The effects of hyperinsulinemia on arterial wall and peripheral muscle metabolism in dogs. Metabolism 1985; 34: 1146-1149.
10. Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, Kraegen EW. Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. Diabetes 1991; 40: 280-289.
11. Falholt K, Jensen I, Lindkaer Jensen S et al. Carbohydrate and lipid metabolism of skeletal muscle in type 2 diabetic patients. Diabet Med 1988; 5: 27-31.
12. Pan DA, Lillioja S, Kriketos AD et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997; 46: 983-988.
13. Phillips DI, Caddy S, Ilic V et al. Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism 1996; 45: 947-950.
14. Simoneau JA, Colberg SR, Thaete FL, Kelley DE. Skeletal muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women. FASEB J 1995; 9: 273-278.
15. Boesch C, Slotboom J, Hoppeler H, Kreis R. In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. Magn Reson Med 1997; 37: 484-493.
16. Brechtel K, Machann J, Jacob S et al. In-vivo 1H-MR spectroscopy: the determination of the intra- and extramyocellular lipid content depending on the insulin effect in the direct offspring of type-2 diabetics. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1999; 171: 113-120.
17. Boesch C, Kreis R. Observation of intramyocellular lipids by 1H-magnetic resonance spectroscopy. Ann N Y Acad Sci 2000; 904: 25-31.
18. Thamer C, Machann J, Bachmann O et al. Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivity. J Clin Endocrinol Metab 2003; 88: 1785-1791.
19. Perseghin G, Scifo P, Pagliato E et al. Gender factors affect fatty acids-induced insulin resistance in nonobese humans: effects of oral steroidal contraception. J Clin Endocrinol Metab 2001; 86: 3188-3196.
20. Hwang JH, Pan JW, Heydari S, Hetherington HP, Stein DT. Regional differences in intramyocellular lipids in humans observed by in vivo 1H-MR spectroscopic imaging. J Appl Physiol 2001; 90: 1267-1274.
21. Polgar J, Johnson MA, Weightman D, Appleton D. Data on fibre size in thirty-six human muscles. An autopsy study. J Neurol Sci 1973; 19: 307-318.
22. 1H NMR spectroscopy study. Diabetologia 1999; 42: 113-116.
23. Jacob S, Machann J, Rett K et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999; 48: 1113-1119.
24. Perseghin G, Scifo P, De Cobelli F et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999; 48: 1600-1606.
25. Virkamaki A, Korsheninnikova E, Seppala-Lindroos A et al. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 2001; 50: 2337-2343.
26. Forouhi NG, Jenkinson G, Thomas EL et al. Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. Diabetologia 1999; 42: 932-935.
27. Luzi L, Perseghin G, Tambussi G et al. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 2003; 284: E274-E280.
28. Sinha R, Dufour S, Petersen KF et al. Assessment of skeletal muscle triglyceride content by (1) H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 2002; 51: 1022-1027.
29. Hurley BF, Nemeth PM, Martin WH III, Hagberg JM, Dalsky GP, Holloszy JO. Muscle triglyceride utilization during exercise: effect of training. J Appl Physiol 1986; 60: 562-567.
30. Essen-Gustavsson B, Tesch PA. Glycogen and triglyceride utilization in relation to muscle metabolic characteristics in men performing heavy-resistance exercise. Eur J Appl Physiol Occup Physiol 1990; 61: 5-10.
31. DeFronzo RA, Ferrannini E, Sato Y, Felig P, Wahren J. Synergistic interaction between exercise and insulin on peripheral glucose uptake. J Clin Invest 1981; 68: 1468-1474.
32. Horton ES. Exercise and decreased risk of NIDDM. N Engl J Med 1991; 325: 196-198.
33. Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab 2001; 86: 5755-5761.
34. Etgen GJ Jr, Jensen J, Wilson CM, Hunt DG, Cushman SW, Ivy JL. Exercise training reverses insulin resistance in muscle by enhanced recruitment of GLUT-4 to the cell surface. Am J Physiol 1997; 272: E864-E869.
35. Ploug T, Stallknecht BM, Pedersen O et al. Effect of endurance training on glucose transport capacity and glucose transporter expression in rat skeletal muscle. Am J Physiol 1990; 259: E778-E786.
36. Dobbins RL, Szczepaniak LS, Bentley B, Esser V, Myhill J, McGarry JD. Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 2001; 50: 123-130.
37. Boden G, Lebed B, Schatz M, Homko C, Lemieux S. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001; 50: 1612-1617.
38. Bachmann OP, Dahl DB, Brechtel K et al. Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 2001; 50: 2579-2584.
39. Stannard SR, Thompson MW, Fairbairn K, Huard B, Sachinwalla T, Thompson CH. Fasting for 72 h increases intramyocellular lipid content in nondiabetic, physically fit men. Am J Physiol Endocrinol Metab 2002; 283: E1185-E1191.
40. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.
41. Baden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994; 93: 2438-2446.
42. Greco AV, Mingrone G, Giancaterini A et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002; 51: 144-151.
43. Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 2003; 26: 30-35.
44. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes. defining their role in the development of insulin resistance and β-cell dysfunction. Eur J Clin Invest 2002; 32 (Suppl. 3): 14-23.
45. Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rossetti L. Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest 1997; 99: 2173-2182.
46. Goldstein BJ, Ahmad F, Ding W, Li PM, Zhang WR. Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases. Mol Cell Biochem 1998; 182: 91-99.
47. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-176.
48. Stumvoll M, Häring H. The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor γ. Diabetes 2002; 51: 2341-2347.
49. Tahvanainen E, Syvanne M, Frick MH et al. Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study Investigators. J Clin Invest 1998; 101: 956-960.
50. Baier LJ, Permana PA, Yang X et al. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest 2000; 106: R69-R73.
51. Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 1996; 97: 2569-2575.
52. Lin J, Wu H, Tarr PT et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002; 418: 797-801.
53. Mammarella S, Romano F, Di Valerio S et al. Interaction between the G1057D variant of IRS-2 and overweight in the pathogenesis of type 2 diabetes. Hum Mol General 2000; 9: 2517-2521.
54. Stefan N, Kovacs P, Stumvoll M et al. Metabolic effects of the Gly1057Asp polymorphism in IRS-2 and interactions with obesity. Diabetes 2003; 52: 1534-1540.
55. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000; 355: 1008-1010.
56. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000; 106: 467-472.
57. Matthaei S, Stumvoll M, Kellerer M, Häring HU. Pathophsiology and pharmacological treatment of insulin resistance. Endocr Rev 2000; 21: 585-618.
58. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002; 34: 217-224.
59. Murphy E, Nolan JJ. Insulin sensitiser drugs. Expert Opin Investig Drugs 2000; 9: 1347-1361.
60. Hofmann C, Lorenz K, Braithwaite SS et al. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance. Endocrinology 1994; 134: 264-270.
61. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
62. De Vos P, Lefebvre AM, Miller SG et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 1996; 98: 1004-1009.
63. Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1996; 93: 5793-5796.
64. Maeda N, Takahashi M, Funahashi T et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
65. Yamauchi T, Kamon J, Waki H et al. The mechanisms by which both heterozygous PPARgamma deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001; 276: 41245-41254.
66. Adams M, Montague CT, Prins JB et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-3153.
67. Jucker BM, Schaeffer TR, Haimbach RE et al. Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study. Metabolism 2003; 52: 218-225.
68. Kuhlmann J, Neumann-Haefelin C, Belz U et al. Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats. Diabetes 2003; 52: 138-144.
69. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
70. Miyazaki Y, Hardies LJ, Wajcberg E et al. Effect of piolgitazone on liver fat content, abdmoninal fat distribution, and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). Diabetes 2002; 51 (Suppl. 2): A69.
71. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295.
72. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277: 25226-25232.
73. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
74. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999; 277: E1-E10.